Summary

Eye Allergy Treatment Market Research Report Information By Type (Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Contact Allergic Conjunctivitis, Giant Papillary Conjunctivitis), By Drug Class (Antihistamine, Mast Cell Stabilizer, NASAIDs, Corticosteroid, Decongestants, Immunotherapy Allergy Shots, Others), By Treatment Form (Eyedrops, Injectables, Tablets & Capsules), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies) And By Region Forecast to 2032

Market Overview
In 2022, the market size of cell and gene therapy biomanufacturing was estimated to be USD 12.6 billion. The Cell and Gene Therapy Biomanufacturing market industry is anticipated to witness a compound annual growth rate (CAGR) of 10.60% from USD 13.9 Billion in 2023 to USD 31.2 Billion by 2032 through the forecast period (2024-2032). The primary market drivers that are fostering market growth are the increasing investments in cell and gene therapy research.
The Cell and Gene Therapy Market is experiencing rapid growth, which is driving the Cell and Gene Therapy Biomanufacturing Market forward by increasing demand for manufacturing solutions. Given the promising clinical trial results and the approval of novel cell and gene therapies, there is a growing necessity to increase production in order to satisfy commercialization requirements. The development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure is required due to the exponential growth of the market. In response to the increasing demand for cell and gene therapy products, biomanufacturing companies are investing in advanced technologies, including automation, single-use systems, and closed-system bioreactors. Furthermore, the Cell and Gene Therapy Biomanufacturing Market is experiencing growth because of the market's expansion, which is fostering collaborations, partnerships, and investments in biomanufacturing capacity to address the swiftly changing cell and gene therapy landscape.

Market Segment Insights
Consumables, Equipment, and Software Solutions comprise the Cell and Gene Therapy Biomanufacturing Market segmentation, with respect to product type.
Based on usage, the market segmentation comprises Commercial Stage Manufacturing and Research Stage Manufacturing.
Based on application, the market segmentation comprises Upstream Processing, Harvesting, and Downstream Processing.
The Cell and Gene Therapy Biomanufacturing Market segmentation is based on the end user and includes Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks.

Regional Perspectives

The study offers market insights for North America, Europe, Asia-Pacific, and the Rest of the World by region. The Cell and Gene Therapy Biomanufacturing Market has been dominated by North America as a result of a variety of factors. Initially, the region is home to a thriving ecosystem of pharmaceutical and biotechnology companies that are actively involved in the research and development of cell and gene therapies. Secondly, the market growth is facilitated by the well-established regulatory frameworks and supportive policies for cell and gene therapy manufacturing in North America.
The second-largest market share in the European Cell and Gene Therapy Biomanufacturing market is attributed to the competent workforce. Several factors have contributed to Europe's acquisition of the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market. The region is fortunate to have a skilled personnel, advanced infrastructure, and a well-established biopharmaceutical industry.
The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is anticipated to experience the most rapid rate of growth from 2024 to 2032. The Cell and Gene Therapy Biomanufacturing Market is experiencing the highest compound annual growth rate (CAGR) in the Asia Pacific region because of diverse factors. Initially, the biopharmaceutical industry in the region is experiencing accelerated growth because of the growing investment in research and development, particularly in the fields of cell and gene therapy.

Major Players
Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others are the major players in the Cell and Gene Therapy Biomanufacturing market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 RISING PREVALENCE OF EYE ALLERGY AND EXPANDING GERIATRIC POPULATION
4.2.2 SURGING DRUG LAUNCHES IN ORDER TO MEET HIGH DEMAND
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS ASSOCIATED WITH CONJUNCTIVITIS
4.4 OPPORTUNITY
4.4.1 ONGOING CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL EYE ALLERGY TREATMENT MARKET
6 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 SEASONAL AND PERENNIAL ALLERGIC CONJUNCTIVITIS
6.3 VERNAL KERATOCONJUNCTIVITIS
6.4 ATOPIC KERATOCONJUNCTIVITIS
6.5 CONTACT ALLERGIC CONJUNCTIVITIS
6.6 GIANT PAPILLARY CONJUNCTIVITIS
7 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS
7.1 OVERVIEW
7.2 ANTIHISTAMINE
7.3 MAST CELL STABILIZER
7.4 NSAIDS
7.5 CORTICOSTEROID
7.6 DECONGESTANTS
7.7 IMMUNOTHERAPY ALLERGY SHOTS
7.7.1 SUBCUTANEOUS IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SCIT)
7.7.2 SUBLINGUAL IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SLIT)
7.8 OTHERS
8 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM
8.1 OVERVIEW
8.2 EYEDROPS
8.3 INJECTABLES
8.4 TABLETS & CAPSULES
9 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 ONLINE PHARMACY
9.4 RETAIL PHARMACY
10 GLOBAL EYE ALLERGY TREATMENT MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2022
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
12 COMPANY PROFILES
12.1 JOHNSON & JOHNSON SERVICES, INC
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ABBVIE INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGY
12.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 HAL ALLERGY B.V.
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 NOVARTIS AG
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 BAUSCH + LOMB
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 SANTEN PHARMACEUTICAL CO., LTD.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 ALCON
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 BAYER AG
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES